Prosecution Insights
Last updated: November 20, 2026
Application No. 17/927,616

METHOD OF PRODUCING ALIPHATIC GLYCOSIDE COMPOUND OR SUGAR FATTY ACID ESTER COMPOUND

Final Rejection §103
Filed
Nov 23, 2022
Priority
May 29, 2020 — JP 2020-094792 +1 more
Examiner
LEE, HOI YAN NMN
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tohoku University
OA Round
4 (Final)
38%
Grant Probability
At Risk
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants only 38% of cases
38%
Career Allowance Rate
35 granted / 91 resolved
-21.5% vs TC avg
Strong +75% interview lift
Without
With
+74.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
55 currently pending
Career history
165
Total Applications
across all art units

Statute-Specific Performance

§101
3.0%
-37.0% vs TC avg
§103
42.3%
+2.3% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
17.8%
-22.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 91 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This Office Action is responsive to Applicant’s Amendment and Remarks, filed August 18, 2026. The amendment, filed August 18, 2026, is acknowledged, wherein claim 1 is amended and claims 2 – 3 are canceled. Claims 1 and 4 – 11 are pending in this application and are currently examined. Priority This application is a national stage application of PCT/JP2021/020523, filed May 28, 2021, which claims benefit of foreign priority document JP2020-094792, filed May 29, 2020. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application is pertinent only when interference arises. Withdrawn Rejections The rejection of claims 1 and 4 – 11 in the previous Office Action, dated May 18, 2026, under 35 U.S.C. 102(a)(1) as being anticipated by Castle has been considered and is withdrawn in view of the amended claim 1. The following are modified grounds of rejection necessitated by Applicant’s Amendment, filed August 18, 2026, wherein claim 1 is amended. New Claim Objections Claim 1 is objected to because of the following informalities: Claim 1, line 6, “wherein” should be inserted immediately before “the solid acid catalyst”. Appropriate correction is required. Modified Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1 and 4 – 11 are rejected under 35 U.S.C. 103 as being unpatentable over Castle (University of York Chemistry, 2016, page 1 – 195, cited in the PTO-892 on May 18, 2026) in view of Toda et al. (EP0734762A1, cited in the PTO-892 on June 11, 2025). Castle teaches the synthesis of APGs from levoglucosan: PNG media_image1.png 200 400 media_image1.png Greyscale , wherein R may be C8H17 or C10H21 (page 149, Scheme 71). Thus, Castle teaches the synthesis of APGs reads on the limitations “a method of producing an aliphatic glycoside compound”, “a step of subjecting an intramolecularly dehydrated sugar and an alcohol” to “an addition reaction”, “in the presence of an acid catalyst”, and “the number of carbon atoms constituting the alcohol compound is 2 to 22” of claim 1 as well as “the alcohol compound is 4 to 22” of claim 7 and “saturated aliphatic hydrocarbon” of claim 8. The zeolite used is a solid acid catalysts (page 30, para. 3). Castle explicitly demonstrates the general method for catalyst trials, wherein levoglucosan, alcohol, and catalyst are charged to the same microwave tube and then heated (page 159, para. 2). Thus, the disclosure reads on the limitations of claim 9. Levoglucosan is an anhydrosugar of glucose with a cyclic acetal between carbons 1 and 6. Levoglucosan is synthesized from cellulose degradation reactions (page 41, para. 2). Thus, the disclosure corresponds to the limitations of claims 4 – 6. Castle further teaches that solid acid catalysts include zeolites, clays, zirconias, and ion-exchange resins, and that such solid acids may be applied to a wide range of reactions and substrates (page 42, para. 2). Castle also recognizes limitations associated with zeolite pore structure for longer and sterically hindered alcohols and explicitly suggests further investigation of a wider range of solid acids (page 71, para. 3). However, Castle does not teach a cation exchanger as a catalyst. Toda et al. teach process for the preparation of glycoside compounds (page 2, lines 5 – 6). The process for the preparation of a glycoside compound comprises reacting a saccharide compound in the presence of solid acid catalyst (page 3, lines 14 – 21). To be precise, the process for the preparation of a glycoside compound comprises reacting a saccharide compound with the general formula [Z(OH)q], wherein Z stands for a saccharide skeleton and q for the number of hydroxyl groups connecting to the saccharide skeleton in the presence of a solid acid catalyst with a glycerol derivative having the general formula HO[C3H5(OH)O]x-R, wherein R stands for an aliphatic group having 1 – 22 carbon atoms and s for a number of 1 – 7 (page 3, lines 14 – 25). The reaction is expressed by the following formula: Z(OH)q + HO[C3H5(OH)O]-R1 [Wingdings font/0xE0] [Z(OH)q-1]-O[C3H5(OH)O]-R1, wherein R1 stands for an aliphatic group having 1 – 12 carbon atoms (page 4, lines 15 – 21). This reaction shows that one hydroxyl group of the saccharide compound is replaced with an -O[C3H5(OH)O]x-R1 group, thereby forming an O-glycosidic bond between the saccharide residue and the hydroxy-containing glycerol group. Toda et al. further teach that the solid acid catalysts include ion exchangers, wherein the ion exchange is preferably an acid type cationic exchanger because of easiness in regeneration and the acid type cationic exchangers involve sulfonic acid type (page 5, lines 20 – 25). Furthermore, Toda et al. demonstrate the operability of acid-type cation exchangers in glycoside-forming reactions through working example using acid-form Amberlite IR-120B as a catalyst for the reaction between D-glucose and 1-O-n-hexylglycerol to produce glucopyranoside products (page 12, lines 40 – 42). Thus, Toda et al. demonstrate the feasibility of using acid-form cation exchange resins to produce glucopyranoside products. It would have been prima facie obvious for a person of ordinary skill in the art before the effective filing date of the claimed invention to substitute the β-zeolite solid acid catalyst used by Castle with the acid-type cationic exchanger in view of Toda et al. because Castle teaches that solid acid catalysts include zeolites and ion-exchange resins and further suggests investigating a wider range of solid acids for the levoglucosan/alcohol glycoside-forming reaction, while Toda et al. teach that both zeolites and ion exchangers are suitable solid acid catalysts for glycoside formation and identifies acid-type cationic exchangers as preferred solid acid catalysts. One of ordinary skill in the art would have been motivated to make the substitution because Castle recognizes limitations associated with zeolite pore structure, particularly for longer or sterically hindered alcohols, and explicitly suggests further investigation of other solid acids, while Toda et al. teach that acid-type cationic exchangers are preferred due to the ease of regeneration. One of ordinary skill in the art would have had a reasonable expectation of success because Castle demonstrates that solid acid catalysis promotes formation of alkyl glucopyranosides from levoglucosan and alcohol, and Toda et al. demonstrate that acid-form cation exchange resins successfully catalyze formation of glucopyranoside products from saccharide substrates and hydroxy-containing organic compounds. Regarding claim 4, Castle discloses levoglucosan, which is an intramolecularly dehydrated sugar, as the starting material and Castle states that levoglucosan is an anhydrosugar of glucose having a cyclic acetal between carbons 1 and 6. Formation of this 1,6-cyclic acetal necessarily requires intramolecular condensation between the hydroxyl group at C1 and the hydroxyl group at C6, with elimination of water, to form the internal C1-O-C6 bridge. Thus, the claimed feature that water is elimination from two hydroxyl groups including a hydroxyl group bonded to the carbon atom at the 1-position is inherently disclosed in the levoglucosan of Castle. Regarding claim 5, Castle discloses levoglucosan, which has an intramolecular structure, and states that levoglucosan is an anhydrosugar of glucose. Glucose is an aldose. Thus, the claimed feature is met. Regarding claim 10, Castle discloses that the reaction where levoglucosan reacts with alcohol with no continuous addition of feed or removal of product during the reaction. Regarding claim 11, Castle teaches octanol, which is a liquid, and the sugar will inherently dissolve in octanol. Response to Applicant’s Remarks: Applicant’s Remarks, filed August 18, 2026, have been fully considered and are found to be not persuasive. Applicant argues that the 103 rejection over Castle in view of Toda et al. should be withdrawn because Castle and Toda et al. use different reactants and allegedly proceed by different reaction mechanisms. Applicant characterizes Toda et al. as forming a glycoside through a dehydration reaction between a saccharide and a glycerol derivative by acid-catalyzed ring opening/addition of an alcohol to levoglucosan. The argument is not persuasive because the rejection does not require bodily incorporation of the reactants of Toda or the overall reaction mechanism of Toda et al. into Castle. Castle remains the primary reference and supplies the claimed levoglucosan/alcohol reaction. Toda et al. is relied upon for its teaching concerning the choice of solid acid catalyst. Moreover, Castle recognizes ion exchange resins as a class of solid acid catalysts, and Toda et al. explicitly teach that ion exchangers and zeolites are suitable solid acid catalysts for glycoside-forming reactions, with acid-type cationic exchangers being preferred. Applicant further argues that Castle teaches H-β-zeolite to be the best performing heterogeneous catalyst, including high conversion and selectivity, and therefore a person of ordinary skill would not have been motivated to replace β-zeolite with a cation exchanger. This argument is not persuasive. Castle’s identification of β-zeolite as a preferred or high performing catalyst does not amount to a teaching away from other solid acid catalysts. In fact, Castle recognizes limitations associated with zeolite pore structure, particularly for longer or sterically hindered alcohols, and explicitly suggests further investigation of a wider ranger of solid acids. Thus, Castle provides a reason to consider alternative solid acid catalysts. Toda et al. then provide a specific alternative by teaching acid-type cationic exchangers as preferred solid acid catalysts for glycoside preparation, including the stated advantage of east of regeneration. Applicant also argues that there would have been no reasonable expectation that the cation exchanger of Toda et al. would function in Castle’s reaction because the references concern different substrates and reaction pathways. This argument is not persuasive because the prior art provides evidence of operability for the relevant catalytic function. Castle demonstrates that solid acid catalysis promotes formation of alkyl glucopyranosides from levoglucosan and alcohol. Toda et al. demonstrate that acid-form cation exchange resins successfully catalyze formation of glucopyranoside products from saccharide substrates and hydroxy-containing organic compounds, including working examples using acid-form cation exchange resins. Thus, although the precise substrates and detailed mechanisms differ, one of ordinary skill would have reasonably expected an acid-type cation exchanger to provide the required solid acid catalytic function in Castle’s glycoside-forming process. Conclusion No claim is found to be allowable. Applicant's amendment necessitated the modified ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HOI YAN LEE whose telephone number is 571-270-0265. The examiner can normally be reached Monday - Thursday 7:30 - 17:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, SCARLETT GOON can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /H.Y.L./Examiner, Art Unit 1693 /SCARLETT Y GOON/Supervisory Patent Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

Show 2 earlier events
Nov 07, 2025
Response Filed
Dec 31, 2025
Final Rejection mailed — §103
Mar 26, 2026
Response after Non-Final Action
Apr 21, 2026
Request for Continued Examination
Apr 23, 2026
Response after Non-Final Action
May 18, 2026
Non-Final Rejection mailed — §103
Aug 18, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799151
TRANSLOCATION CONTROL ELEMENTS, REPORTER CODES, AND FURTHER MEANS FOR TRANSLOCATION CONTROL FOR USE IN NANOPORE SEQUENCING
4y 12m to grant Granted Nov 17, 2026
Patent 12747260
SYNTHESIS OF OLIGOMERIC COMPOUNDS COMPRISING PHOSPHOROTHIOATE DIESTER AND PHOSPHODIESTER LINKAGES
4y 10m to grant Granted Sep 29, 2026
Patent 12653805
TARGETING LASP1, EIF4A1, EIF4B AND CXC4 WITH MODULATORS AND COMBINATIONS THEREOF FOR CANCER THERAPY
4y 10m to grant Granted Jun 16, 2026
Patent 12599591
Vemurafenib and salts thereof for use in the treatment of enteroviral infections
5y 0m to grant Granted Apr 14, 2026
Patent 12577227
WDR5 INHIBITORS AND MODULATORS
4y 3m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
38%
Grant Probability
99%
With Interview (+74.9%)
3y 5m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 91 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month